“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
End-to-end solution and parts offer flexibility to verify facilities, assemble higher-volume calls, and dramatically expand overall capacity
FREDERICTON, NB, 14 September 2020 / PRNewswire / – Canada’s leading biotechnology company, LuminUltra, announced that it submitted its GeneCount® COVID-19 RT-qPCR (COVID-19) verification to the US Food and Drug Administration. U. S. (FDA) for Emergency Use Authorization (USA). U. S. ) And Health Canada for Provisional Prescription (IO). With permission to use this key verification component, LuminUltra, a leader in on-the-box molecular diagnostic verification for more than 20 years, will provide a complete clinical description of COVID-19. Verify tailor-made solution for verifying services in North America.
LuminUltra’s GeneCount® COVID-19 RT-qPCR exact verification solution includes several parts that are a comprehensive solution, including: pattern collection kits; insulation reagents; The COVID-19 check; and a variety of qPCR detection verification devices with software for undeniable interpretation of COVID-19 verification effects in less than two hours.
With the approval of COVID-19 verification, LuminUltra will be able to offer flexibility to the right international amenities by offering all or part of the COVID-19 verification factors required of a reputable single company, reducing the need for supplier factors, in line with the granting of amenities to temporarily integrate greater verification capacity. Highlighting its reliable source chain, LuminUltra temporarily responded to the Canadian Government’s desire for verification before this year and has been a key supplier of insulation reagents to the national verification program since April, offering 500,000 controls consistent with the week.
Facilities can check COVID-19 devices based on their respective needs and size, portable qPCR verification devices that can compare up to 16 samples in less than two hours, with large format, high capacity automated qPCR and extraction devices.
“Human diagnostic controls for COVID-19 have evolved a lot and become confusing for users. We are frustrated that services are forced to acquire uncompromising parts for the control of other corporations and to solve chain-of-origin disorders because those products are in high demand. seeking safe answers for patients,” said Pat Whalen, President and CEO of LuminUltra. “We work tirelessly to get flexible answers where we are confident, all from a single company that has a proven track record of assembly demand.
LuminUltra has a history of innovation in biological control. In addition to clinical diagnostic control, LuminUltra is also the author of GeneCount Environmental Monitoring Solutions, an on-site environmental tracking formula that detects the presence of SARS-CoV-2, the virus that causes COVID. -19, on surfaces, in the air or in wastewater. This tracking formula, introduced in May 2020, allows companies, construction managers, hotels, cruise operators, service providers and others to know disinfection protocols and identify possible asymptomatic and pre-replacement. GeneCount qPCR devices, whether portable or high capacity, can also run environmental verification, providing a comprehensive technique for managing a pandemic. Environmental verification research and progress have helped ensure reliable and ready environmental verification. clinical trial on the market.
Resources, adding photos of geneCount qPCR products and app photos, can be found here.
At luminUltra Founded in 1995, LuminUltra is a Canadian-based biological diagnostic testing company operating in 6 countries and widely identified globally as a leader in the progression of tests and reagents for environmental, commercial and diagnostic monitoring and is a key supplier of COVID. -19 clinical trial reagents for the Government of Canada. Customers in more than 80 countries rely on LuminUltra technology, production reliability and excellence in stopover service to provide their must-have facilities in one state. For more information, visit luminultra. com/clinical
View content: http://www. prnewswire. com/news-releases/biotechnology-leader-luminultra-submits-covid-19-clinical-diagnostic-testing-kit-for-regulatory-authorization-in-us-canada- 301130040 . html
LUMINUltra SOURCE